Six Things to Know in August 2022 1st Week

December 10, 2022

J&J Halts Phase 3 Depression Program Over Efficacy Concerns

March 12, 2025

Life Sciences Voice Top Five Newsletter

May 17, 2024

Must Read

Despite a mid-stage failure, Bausch + Lomb moves a medication for dry eye condition to Phase 3

August 28, 2026

Top 10 Digital Risks Facing Biotech Companies

August 28, 2026

AI in GMP Compliance

August 28, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Novo Launches Late-Stage Trial of Lower-Dose Wegovy Pill for Weight Management

Oregon Study Finds Triple-Drug Regimen Kept Infant Macaques HIV-Free for One Year

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Despite a mid-stage failure, Bausch + Lomb moves a medication for dry eye condition to Phase 3

Biokin’s Iza-Bren Meets Primary Endpoint in Phase 3 Panku-Lung01 Lung Cancer Trial

Definium Bags Major Phase 3 Victory With LSD Formula

Taiho and Cullinan Report Phase 3 Progression-Free Survival Win for Zipalertinib

Leo Pharma Pens Mega Deal to Buy Tanabe’s Skin Disease Drug

PTC Therapeutics Acquires ST-920 Fabry Disease Gene Therapy Program From Sangamo

Zealand Bags Huge Money By Selling Rights to Takeda’s Blood Cancer Drug

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

Top 10 Digital Risks Facing Biotech Companies

AI in GMP Compliance

The Future of Global Drug Regulation

Why Pharmaceutical Companies Need AI Factories

Editorial Team

Third antibody treatment for early COVID infection approved by the FDA

Editor Picks

Six Things to Know in August 2022 1st Week

J&J Halts Phase 3 Depression Program Over Efficacy Concerns

Life Sciences Voice Top Five Newsletter

Must Read

Despite a mid-stage failure, Bausch + Lomb moves a medication for dry eye condition to Phase 3

Top 10 Digital Risks Facing Biotech Companies

AI in GMP Compliance

Hot Topics

About Us

Follow Us